With respect to the current meta-analysis, the effect of MDM2 309 was analyzed in 2233 cases and 7164 controls from 10 case-control studies, including global registries like the Nurses’ Health Study (NHS) and the Molecular Markers in Treatment of Endometrial Cancer (MoMaTEC). Here, MDM2 is linked to endometrial cancer.